# OnCo record nct07654530 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07654530/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07654530", "NCT07654530" ;
  schema:name "Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC."@en ;
  schema:alternateName "SIAG-BTC"@en ;
  schema:description "A phase 2 trial of ipilimumab, sintilimab, gemcitabine and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07654530/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07654530> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "gallbladder-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/sintilimab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/nab-paclitaxel/> .